Assessment of Outcome of Hepatic Resection for Extremely Elderly Patients With a Hepatic Malignancy.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 03 07 2019
revised: 24 07 2019
accepted: 25 07 2019
entrez: 10 11 2019
pubmed: 11 11 2019
medline: 15 11 2019
Statut: ppublish

Résumé

We aimed to assess surgical outcome and long-term survival after elective hepatic resection for hepatocellular carcinoma (HCC) and colorectal liver metastasis (CRLM) in patients aged 80 years or older. This study included 100 patients aged 70 years or older, who underwent hepatic resection for HCC or CRLM between January 2000 and December 2012. Outcomes and clinicopathological data were compared between the elderly (aged 70-79 years; n=84) and extremely elderly groups (aged 80 years or older; n=16). Incidence of postoperative complications, in-hospital mortality, and postoperative OS in the extremely elderly group were comparable with those of the elderly group. In patients with HCC, the extremely elderly group was associated with shorter DFS (p=0.030) in univariate analysis, while multivariate analysis showed significant and independent factors of cancer recurrence. Hepatic resection for HCC and CRLM in patients aged 80 years and older may be safe and acceptable with appropriate selection. For HCC in patients aged 80 years and older, hepatic resection may be effective when negative surgical margins can be achieved.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
We aimed to assess surgical outcome and long-term survival after elective hepatic resection for hepatocellular carcinoma (HCC) and colorectal liver metastasis (CRLM) in patients aged 80 years or older.
PATIENTS AND METHODS METHODS
This study included 100 patients aged 70 years or older, who underwent hepatic resection for HCC or CRLM between January 2000 and December 2012. Outcomes and clinicopathological data were compared between the elderly (aged 70-79 years; n=84) and extremely elderly groups (aged 80 years or older; n=16).
RESULTS RESULTS
Incidence of postoperative complications, in-hospital mortality, and postoperative OS in the extremely elderly group were comparable with those of the elderly group. In patients with HCC, the extremely elderly group was associated with shorter DFS (p=0.030) in univariate analysis, while multivariate analysis showed significant and independent factors of cancer recurrence.
CONCLUSION CONCLUSIONS
Hepatic resection for HCC and CRLM in patients aged 80 years and older may be safe and acceptable with appropriate selection. For HCC in patients aged 80 years and older, hepatic resection may be effective when negative surgical margins can be achieved.

Identifiants

pubmed: 31704863
pii: 39/11/6325
doi: 10.21873/anticanres.13843
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6325-6332

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Takashi Horiuchi (T)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan horiuchi@jikei.ac.jp.

Koichiro Haruki (K)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Hiroaki Shiba (H)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Taro Sakamoto (T)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Nobuhiro Saito (N)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Yoshihiro Shirai (Y)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Ryota Iwase (R)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Yuki Fujiwara (Y)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Katsuhiko Yanaga (K)

Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH